Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals, Inc. (MIRM) – Form 4 insider transaction filing. SVP & Global Controller Jolanda Howe reported three transactions between 1–3 July 2025.
- 1 Jul 2025: 1,041 restricted stock units (RSUs) converted into an equal number of common shares (Transaction Code M). Post-conversion ownership temporarily rose to 3,467 shares.
- 2 Jul 2025: 564 shares sold at $48.25 (Code S) to cover tax-withholding obligations tied to the RSU vesting.
- 3 Jul 2025: 477 shares sold at $49.08 under a pre-existing Rule 10b5-1 plan adopted 16 Dec 2024.
Following these actions, Howe’s direct beneficial ownership declined from 3,467 to 2,426 common shares. All 1,041 RSUs from the reported award are now fully settled, leaving no outstanding derivative securities.
The RSU grant vests in three equal annual installments that began on 1 Jul 2023. All reported transactions were executed by a single insider; no joint filings were made.